Research
Cell-free RNA signatures derived from the tumor microenvironment predict outcomes of CAR T therapy in large B cell lymphoma
Cell Reports Medicine · By Conor Loy, Glory Agun, Katie Maurer, Anna Bosch-Vilaseca, Daria Potapova, Caron A. Jacobson, Jerome Ritz & Iwijn De Vlaminck ·
The Brief
- Plasma cell-free RNA collected before anti-CD19 CAR T cell infusion predicts long-term treatment response in large B cell lymphoma, according to Loy et al.
- The study uses tumor microenvironment-derived archetypes and unbiased feature discovery to identify these RNA signatures.
- The authors report that plasma cell-free RNA captures signals from the tumor microenvironment.
Why it matters
A blood-based RNA signature measured before infusion could help clinicians anticipate which lymphoma patients are likely to respond durably to CAR T therapy, without needing tumor biopsies.
Who’s affected
- clinical oncologists and hematologists treating large B cell lymphoma
- researchers working on CAR T cell therapy and liquid biopsy biomarkers
- #cell-free rna
- #car t therapy
- #lymphoma
- #biomarkers
- #liquid biopsy
- #tumor microenvironment
Loy et al. show that plasma cell-free RNA collected before anti-CD19 CAR T cell infusion predicts long-term treatment response. Using tumor microenvironment-derived archetypes and unbiased feature discovery, they find that plasma cell-free RNA captures signals from the tumor…